Inhibition of lignocaine metabolism by β-adrenoceptor antagonists in rat and human liver microsomes

References

• Baker J. K., Rauls D. O., Borne F. R. Correlation of biological activity and HPLC retention index for a series of propranolol, barbiturate and anthranilic acid analogues. Journal of Medicinal Chemistry 1979; 22: 1301
   PubMedGoogle Scholar
• Bax N. D. S., Lennard M. S., Tucker G. T. Inhibition of antipyrine metabolism by beta-adrenoceptor antagonists. British Journal of Clinical Pharmacology 1983; 12: 779–784
   Google Scholar
• Bax N. D. S., Jones R. W., Lennard M. S., Tucker G. T., Woods H. F. Penbutolol and propanolol: a comparison of their effects on antipyrine clearance in man. British Journal of Clinical Pharmacology 1985; 19: 593–596
   PubMed Web of Science ®Google Scholar
• Conrad K. A., Nyman D. W., Tuscon M. S. Lidocaine elimination: effects of metoprolol and propranolol. Clinical Pharmacology and Therapeutics 1980; 33: 133–138
   Google Scholar
• Deacon C. S., Lennard M. S., Bax N. D. S., Woods H. F., Tucker G. T. Inhibition of oxidative drug metabolism by beta-adrenoceptor antagonists is related to their lipid solubility. British Journal of Clinical Pharmacology 1981; 12: 429–430
   Google Scholar
• Facino R. M., Lanzani R. Interaction of a series of beta-adrenergic blocking drugs with rat hepatic microsomal monooxygenase. Pharmacological Research Communications 1979; 11: 433–445
   Google Scholar
• Hermansson J., Glaumann H., Karlen B., von Bahr C. Metabolism of lidocaine in human liver in vitro. Acta Pharmacologica et Toxicologica 1980; 47: 49–52
   PubMedGoogle Scholar
• Hinderling P. H., Schmidlin O., Seydel J. K. Quantitative relationships between structure and pharmacokinetics of beta-adrenoceptor blocking agents in man. Journal of Pharmacokinetics and Biopharmaceutics 1984; 12: 263–287
   PubMedGoogle Scholar
• Levin W., Kuntzman R. Biphasic decrease of radioactive hemoprotein from liver microsomal co-binding particles. Molecular Pharmacology 1969; 5: 499–506
   PubMed Web of Science ®Google Scholar
• Lowry O. H., Rosenbraugh N. H., Farr A. L., Randall R. J. Protein measurement with the folin phenol reagent. Journal of Biological Chemistry 1951; 193: 265–275
   PubMed Web of Science ®Google Scholar
• Mazel P. Experiments illustrating drug metabolism in vitro. Fundamentals of Drug Metabolism and Disposition, B. N. LaDu, H. G. Mandel, E. L. Way. Williams & Wilkins, Baltimore 1972; 546–582
   Google Scholar
• Nakagawa Y., Hiraga K., Suga T. Biological fate of butyrated hydroxytoluen (BHT): binding in vitro of BHT to liver microsomes. Chemical and Pharmaceutical Bulletin 1979; 27: 480–485
   PubMed Web of Science ®Google Scholar
• Ochs H. R., Skanderra D., Abernathy D. R., Greenblatt D. J. Effect of penbutolol on lidocaine kinetics. Arzneimiitel Forschung 1983; 33: 1680–1681
   Google Scholar
• Ochs H. R., Hajdu P., Greenblatt D. J. Pharmacokinetics and dynamics of penbutolol in humans: evidence for pathway-specific stereoselective clearance. Klinische Wochenschrift 1986; 64: 636–641
   PubMedGoogle Scholar
• Omura T., Sato R. The carbon monoxide-binding pigment of liver microsomes. II. Solubilization, purification and properties. Journal of Biological Chemistry 1964; 239: 2379–2385
   PubMed Web of Science ®Google Scholar
• Pritchard J. F., Schneck D. W., Hayes A. H. The inhibition of rat hepatic microsomal propranolol by a covalently bound reactive metabolite. Research Communications in Chemical Pathology and Pharmacology 1980; 27: 211–221
   PubMedGoogle Scholar
• Schneck D. W., Pritchard J. F. The inhibitory effect of propranolol and pretreatment on its own metabolism in the rat. Journal of Pharmacology and Experimental Therapeutics 1981; 218: 575–581
   PubMed Web of Science ®Google Scholar
• Shaw L., Lennard M. S., Tucker G. T., Bax N. D. S., Woods H. F. Irreversible binding and metabolism of propranolol in human liver microscomes—relationship to polymorphic oxidation. Biochemical Pharmacology 1987; 35: 2283–2288
   Google Scholar
• Smith A. J., Tucker G. T. Kinetics and biotransformation of adrenergic inhibitors. Adrenergic Activators and Inhibitors, Part II, L. Szekeres. Springer-Verlag, Berlin 1981; 417–501
   Google Scholar
• Street J. A., Gonda I., Parkinson H., Hemsworth B. A. Lung accumulation of some beta-adrenoceptor antagonists. Journal of Pharmacy and Pharmacology 1978; 30S: 59P
   Google Scholar
• Suzuki T., Fujita S., Kawai R. Precursor-metabolite interaction in the metabolism of lidocaine. Journal of Pharmaceutical Sciences 1984; 73: 136–138
   Google Scholar
• Taylor D. C., Pownall R., Burke W. The absorption of beta-adrenoceptor antagonists in rat in situ small intestine; the effect of lipophilicity. Journal of Pharmacy and Pharmacology 1985; 37: 280–283
   PubMed Web of Science ®Google Scholar
• Topham J. C. Relationship between difference spectra and metabolism. Biochemical Pharmacology 1970; 19: 1695–1701
   Google Scholar
• Tucker G. T., Bax N. D. S., Lennard M. S., Crewe H. K., Woods H. F. Lack of effect of atenolol on antipyrine clearance. British Journal of Clinical Pharmacology 1982; 14: 743–744
   Google Scholar
• Tucker G. T., Bax N. D. S., Lennard M. S., Al-Asady S. A. H., Bharaj H. S., Woods H. F. Effect of beta-adrenoceptor antagonists on the pharmacokinetics of lignocaine. British Journal of Clinical Pharmacology 1984; 17: 21S–28S
   Google Scholar
• von Bahr C., Hedlund I., Karlen B., Backstrom D., Grasdalen H. Evidence for two catalytically different binding sites of liver microsomal cytochrome P-450: importance of species and sex differences in oxidation pattern of lidocaine. Acta Pharmacologica et Toxicologica 1977; 4: 39–48
   Google Scholar
• Woods P. B., Robinson M. L. An investigation of the comparative liposolubilities of beta-adrenoceptor blocking agents. Journal of Pharmacy and Pharmacology 1981; 33: 172–173
   PubMed Web of Science ®Google Scholar
• Ylitalo P., Linden I.-B., Pentila A., Vapaatalo H. Distribution of beta-adrenoceptor blocking drugs into cerebrospinal fluid in rats. Acta Pharmacologica et Toxicologica 1986; 58: 84–87
   Google Scholar